BioStem Technologies (BSEM) vs CervoMed (CRVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioStem Technologies (BSEM) has outperformed CervoMed (CRVO) over the past year, losing 45.0% versus a loss of 63.1%. Over five years, BSEM leads with a +88.6% price change compared with -90.9% for CRVO. CervoMed is the larger company by market cap ($49.6 million vs $49.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSEM | CRVO |
|---|---|---|
| Share price | $2.64 | $3.28 |
| Market cap | $49.29M | $49.59M |
| 1-day change | +10.46% | +3.14% |
| YTD return | -30.71% | -58.48% |
| 1-year return | -45.00% | -63.15% |
| 5-year return | +88.57% | -90.89% |
| P/E ratio (TTM) | 3.00 | — |
| Forward P/E | 9.10 | — |
| EPS (TTM) | $0.88 | $-3.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $10.00 |
| 52-week low | $2.25 | $2.13 |
| Distance from 52-week high | -68.57% | -67.20% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +165.15% | +369.51% |
| Average volume | 124.14K | 339.08K |
| Shares outstanding | 18.67M | 15.12M |
| Employees | 73 | 15 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BSEM has outperformed CRVO by 18.1 percentage points over the past year.
About BioStem Technologies
BSEM stock →BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Healthcare · Biotechnology · 73 employees
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Healthcare · Biotechnology · 15 employees
BSEM vs CRVO FAQ
Which is bigger, BioStem Technologies or CervoMed?
CervoMed (CRVO) is larger, with a market capitalization of $49.59M compared with $49.29M for BioStem Technologies (BSEM).
Which stock has performed better over the past year, BSEM or CRVO?
BSEM returned -45.00% over the past 12 months, compared with -63.15% for CRVO (price return, excluding dividends). Past performance does not predict future results.
Are BioStem Technologies and CervoMed in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.